The Science 37 Direct-to-Patient Site in Action: A Fully Decentralized Trial for a Rare Vascular Disorder

A biopharma company was planning a Phase III, randomized, double-blind, placebo-controlled clinical trial for a drug to treat a rare and serious vascular disorder. Learn how the Science 37 Direct-to-Patient Site:

• Made it easier for patients with a rare cardiovascular disease to participate from home
• Delivered high-quality, compliant data to support the sponsor’s regulatory submission
• Had 100% patient retention in the first 4 months

Discover how a virtual site reduced patient burden with remote clinical trial conduct and delivered high-quality, compliant data to support the sponsor’s regulatory submission.